1-17 algodystrophy---
TRANSCRIPT
![Page 1: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/1.jpg)
Algodystrophy (AD)
Prof. Hazem Abdel Azeem (MD)
Cairo University
![Page 2: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/2.jpg)
Transient osteoporosis of hip
Algodystrophy 1987
H. Azeem H. Mohammadi
New Egyptian Journal of Medicine
PublicationPublicationAD
![Page 3: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/3.jpg)
AD
Alogodystrophy a Neurodystrophic
Disorders
Alogodystrophy a Neurodystrophic
Disorders
![Page 4: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/4.jpg)
AD
Characters:
Pain.
Swelling.
Trophic changes.
Functional incapacity.
![Page 5: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/5.jpg)
ADAlgodystrophy
Definition
“The term Algodystrophy covers a group of
painful conditions with association of pain,
vasomotor and trophic changes, functional
impairment localized in the distal parts of the
body”
![Page 6: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/6.jpg)
ADTerminology* Algodystrophy (AD)
o Sudecks bone atrophy 1900.
o Reflex sympathetic dystrophy (RSD).
o Decalcifying alogdystrophy.
![Page 7: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/7.jpg)
AD
o Post traumatic painful osteoporosis.
o Regional migratory osteoporosis.
o Shoulder-hand syndrome.
o Transient osteoporosis.
![Page 8: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/8.jpg)
AD
Historical
Clinical: Causalgia.
Painful soft tissue oedema
Radiological : Acute bone atrophy
1st: Sudecks bone atrophy 1900
![Page 9: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/9.jpg)
AD
Main Aetiological Fractors In 250
Cases Of Algodystrophy
![Page 10: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/10.jpg)
![Page 11: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/11.jpg)
AD
Sudecks
Vincent
Lequesne
Mohamadi & Azeem
Réne
1900
1962
1967
1987
1994
Literature
![Page 12: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/12.jpg)
![Page 13: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/13.jpg)
AD
Algodystrophy Following trauma
Neglected Minor Trauma
* Sprains. * Fractures.
* Conyusions. * Dislocations.
![Page 14: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/14.jpg)
AD
Algodystrophy with locomotor disorders
* Arthritis.
* Tendonitis.
* Gout…etc.
![Page 15: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/15.jpg)
AD
Algodystrophy with metabolic disorders
* Diabetes mellitus.
* Gout.
Drug induced:
-Barbiturates. - Antithyroid.
- AntiTB. - Alocohol.
![Page 16: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/16.jpg)
AD
Algodystrophy with peripheral nerves disorders
* Radiculagia..
* Neuroma.
* Nerve entrapment.
* Neuropathy.
![Page 17: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/17.jpg)
AD
Algodystrophy
with vascular disease
• Ischaemia.
• Peripheral arterial disease.
![Page 18: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/18.jpg)
ADAlgodystrophy
with CNS distributions
• Hemiplegie.
• Meningeal and cerebral hage.
• Parkinsonian disease.
• Epilpsy.
![Page 19: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/19.jpg)
ADAlgodystrophy
Following surgery
Minor Soft Tissues inte
• Meningeal and cerebral hage.
• Parkinsonian disease.
• Epilpsy.
![Page 20: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/20.jpg)
AD
![Page 21: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/21.jpg)
AD
Pathophysiology
Theories:
• Neurovascular dystrophy
• Bone remodeling
• Hormonal regulation
• Biomechanical
![Page 22: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/22.jpg)
AD
Biochemical Theory
![Page 23: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/23.jpg)
AD
Hemoral Theory
? Parathyroid
? Calcitonin
? 1-25 diydroxicalciferol
Relation to ostoclastic activity
![Page 24: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/24.jpg)
AD
Disturbance of Bone Remodelling Unbalanced
Cellular Coupling Osteoblaste X osteoclast
Result: Localized Trabicular bone loss
![Page 25: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/25.jpg)
AD
Neurocasular Theory
Vicious circle, pain stiffness, fear
over sympathetic tone, vasospasm,
ischemia, vasodilatation, oedema, pain
mediators, etc
![Page 26: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/26.jpg)
Neurovascular
Vasospasm
ischaemia
Vasodilation
Oedema Pain Stiffness
Over sympathetic tone
![Page 27: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/27.jpg)
AD
Pathology
Synoial membrane normal
Articular cartilage normal
Periarticular tissue normal
No inflammatory signs
![Page 28: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/28.jpg)
![Page 29: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/29.jpg)
ADPathology
Osteoblastic poor activity
Subchondral cortical and
cancellous resprotion
Wide marrow spaces
Micro fractures
![Page 30: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/30.jpg)
![Page 31: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/31.jpg)
![Page 32: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/32.jpg)
![Page 33: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/33.jpg)
AD
The sites most commonly affected are the
wrist and hand (28%;, shoulder (27%),
ankle and foot (24%), knee (10%), elbow
(6%) and hip (5%). The condition occurs
mainly in people aged between 40 and 65
years.
![Page 34: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/34.jpg)
AD
![Page 35: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/35.jpg)
AD
• Clinical basis & staging
• Radiography
• Bone scintography
Diagnosis
![Page 36: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/36.jpg)
AD
MRI
Densitometry
Lab. work up
Histopathology
Biopsy [core]
![Page 37: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/37.jpg)
Clinical Picture and stages
Stage I: 2 to 3 months. * Pain : - Dull - Causalgic * Vasomotor:
- Redness to bluishness.
-Swelling. - Wormth - Oedema.
* Refrain from movement (Painful)
(Pseudoinflammatory signs).
![Page 38: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/38.jpg)
AD
Stage II:
* Trophic changes:
- Skin atrophy. - Atrophic hairs.
- Tappering fingers. - Atrophic nails
* Joints stiffness.
Clinical Picture and stages
![Page 39: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/39.jpg)
AD
Stage III:
* Joints increase in stiffness to fibrous
ankylosis.
* Decrease in the pseudoinflammatory
signs.
Clinical Picture and stages
![Page 40: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/40.jpg)
Lab:-
not constant Hydroxyprolinuria
increased erosive reemodelling
(osteoclast) Osteocalcin level increase
increased osteoblastic activity ESR
normal
![Page 41: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/41.jpg)
ADRadiology• Diffuse rarifaction, spotty, patchy,
widened trabiculations
• Cortical erosions
• Total loss of bone structure, by moth
eaten appearance
• Normal joints
![Page 42: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/42.jpg)
AD
![Page 43: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/43.jpg)
AD
![Page 44: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/44.jpg)
AD
![Page 45: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/45.jpg)
AD
Bone scanScintography
Hot area
[remodelling activity]
![Page 46: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/46.jpg)
AD
![Page 47: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/47.jpg)
AD
Densitometry
Weak photon densitometry image
[ decrease bone mass]
![Page 48: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/48.jpg)
AD
![Page 49: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/49.jpg)
AD
Pathology
Core biopsy:•Periosteocytic lysis of cortical and
cancellous bone
• Foci of remodelling activity
• Osteoclastic bone resorption
![Page 50: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/50.jpg)
AD
![Page 51: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/51.jpg)
AD
Personal Experience
Post traumatic
Sudecks´ bone atrophy
![Page 52: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/52.jpg)
AD
![Page 53: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/53.jpg)
AD
![Page 54: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/54.jpg)
AD
![Page 55: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/55.jpg)
AD
![Page 56: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/56.jpg)
AD
![Page 57: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/57.jpg)
AD
![Page 58: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/58.jpg)
AD
![Page 59: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/59.jpg)
AD
![Page 60: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/60.jpg)
AD
![Page 61: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/61.jpg)
AD
![Page 62: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/62.jpg)
AD
![Page 63: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/63.jpg)
AD
![Page 64: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/64.jpg)
AD
Treatment The short-term aims of the treatment of
algodystrophy are the following: To relieve the pain. To correct or prevent vasomotor disorders. To prevent bone demoralization. To prevent trophic change and ankylosis. To reduce the duration of functional incapacity.
![Page 65: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/65.jpg)
AD
Treatment
Medical treatment.
Local injections.
Sympathetic block.
Nerve block.
Physical and rehabilitation.
Accupuncture.
Psychotherapy.
Surgical treatment.
![Page 66: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/66.jpg)
AD
Medical Treatment
NSAIDA.
Vasodilators.
Corticosteroids.
Betabolckers.
Calcitonin.
![Page 67: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/67.jpg)
Calcitonin ( synthetic salmon Calcitonin)
Significantly shortens the duration of
functional incapacity, which can otherwise last for
a year or more, by preventing further bone
demineralization and promoting rapid
remineralization.
Is safe and well tolerated; there are known I
contraindications.
![Page 68: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/68.jpg)
Calcitonin ( synthetic salmon Calcitonin)
Particularly when given in early-stage disease
Rapidly relieves pain, often completely.
Alleviates the other symptoms.
Increases joint mobility.
Next
![Page 69: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/69.jpg)
AD
Calcitonin
*In Moderate Cases:
- 100 I.U. every day. For 3months.
![Page 70: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/70.jpg)
AD
Calcitonin *In Severe Cases:
- 100 I.U. every day. For 2 to 4
weeks followed by 100 IU every other
day for 2 months.
![Page 71: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/71.jpg)
AD
Calcitonin *Dose is versatile.
- course can be repeated spaced 3
monthly.
![Page 72: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/72.jpg)
AD
Local Injection
•Periarticular (not intraarticular) and in
trigger points.
• Local anaesthetic + hydrocortisone.
![Page 73: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/73.jpg)
AD
• Sympathetic ganglion block.
• Nerve block.
![Page 74: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/74.jpg)
AD
• Physical and rehabilitaon
therapy.
•Accupuncture.
• Psychotherapy.
![Page 75: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/75.jpg)
AD
Surgical Treatment * In persistent Acute Manifestation
- Sympathectomy
Cervical or Lumber.
* In Chronic Cases
- For release
![Page 76: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/76.jpg)
AD
![Page 77: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/77.jpg)
AD
![Page 78: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/78.jpg)
AD
![Page 79: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/79.jpg)
AD
![Page 80: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/80.jpg)
AD
![Page 81: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/81.jpg)
AD
![Page 82: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/82.jpg)
AD
![Page 83: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/83.jpg)
AD
Alogodystrophy?
![Page 84: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/84.jpg)
AD
* Prognosis:
√ Recovery is common
Or √ Stiff atrophic hand
![Page 85: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/85.jpg)
AD
Unsatisfactory situation
![Page 86: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/86.jpg)
AD
*Problem: Diagnosis
Clinical diagnosis
Aetiological diagnosis
Pathological diagnosis
Unsatisfactory situation
![Page 87: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/87.jpg)
Thank You
![Page 88: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/88.jpg)
AD
![Page 89: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/89.jpg)
AD
![Page 90: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/90.jpg)
AD
![Page 91: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/91.jpg)
Algodystrophy
Reflex sympathetic dystrophy PROF. HAZEM ABDEL-AZEEM
PROF. OF ORTH, SURGERY
CAIRO UNIVERSITY
![Page 92: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/92.jpg)
Role of Miacalcic
Miacalcic
Relieves oedema
Inhibits the Alogodystrophy
process Relives pain
Increases the rang of
movement Helps in restoration
of normal bone density
Reduces redness
& hypothemia
AD
![Page 93: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/93.jpg)
•A localized syndrome involving pain, oedema and vasomotor disturbances around a joint of joints
•Occurs due to: (1) Trauma eg. Sprains, contusions & dislocations.
(2) Locomotor disorders eg. Arthritis * tenditis
(3) Other disorders eg. Neuropathy, ischaemia & hemiplegia.
Alogodystrophy AD
![Page 94: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/94.jpg)
• Antiosteoclastic
• Anti-inflammatory
• Analgesic
• Vascular effect
Mode of action of Miacalcic AD
![Page 95: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/95.jpg)
• inhibition of the algystrophic process.
•Relief of symptoms.
•Restoration of normal density.
The patient need AD
![Page 96: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/96.jpg)
Miacalcic Relives pain and improves the range of movement in
algodystrophy
AD
![Page 97: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/97.jpg)
Clinical presentation
Algodystrophy
Swelling Pain
Tendernes
Vasomotor
disurbance
Frozen shoulder syndrome
Stiffness
AD
![Page 98: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/98.jpg)
Incidence after colle´s fracture AD
![Page 99: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/99.jpg)
Long-term consequences
persists for > 1 year & may nead to loss of function
Bone loss Malunio Pain & stiffness
Deformity. Shortening of the radius.Radio-ulnar joint dislocation.
> 10% loss in cortical bone. > 25% loss in trabecular bone.
AD
![Page 100: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/100.jpg)
Miacalcic in Alogodystrophy
• Caldtonin has proved to be the most e/fei agent in
the treatment of Sudeck's disease. It proves
microcirculatory disturbances.
• Reduces bone pain.
• Inhibits the pathologically increased
resorption“
Ada Bossany, Endocr, Jugoslav., 1997
AD
![Page 101: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/101.jpg)
Problem: Treatment
AD
![Page 102: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/102.jpg)
AD
![Page 103: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/103.jpg)
AD
![Page 104: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/104.jpg)
AD
![Page 105: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/105.jpg)
AD
![Page 106: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/106.jpg)
AD
![Page 107: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/107.jpg)
Difficult task:-
Low incidence
Refusing interference
Neurotic
Expensive lab & Rad. Work up
? Expensive drugs
AD
![Page 108: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/108.jpg)
AD
Calcitonin *In Severe Cases:
- 100 I.U. /day.
- Sc. Or IM. For 2 to 4 weeks.
*In Moderate.
![Page 109: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/109.jpg)
AD
![Page 110: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/110.jpg)
AD
Miacalcic reduces vasomotor and inflammatory symptoms (e.g. oedema and changes in the appearance of the skin) and restores the mobility of the affected joint.
![Page 111: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/111.jpg)
AD
![Page 112: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/112.jpg)
AD
![Page 113: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/113.jpg)
AD
![Page 114: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/114.jpg)
AD
![Page 115: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/115.jpg)
AD
![Page 116: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/116.jpg)
AD
![Page 117: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/117.jpg)
AD
![Page 118: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/118.jpg)
AD
Treatment
comprehensive approach
Treatment of injury
Block of sympathetic flow
Active movements
Psyscological support
Calcition
![Page 119: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/119.jpg)
AD
![Page 120: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/120.jpg)
AD
![Page 121: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/121.jpg)
AD
![Page 122: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/122.jpg)
AD
![Page 123: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/123.jpg)
AD
![Page 124: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/124.jpg)
AD
![Page 125: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/125.jpg)
AD
© Algodystrophy: * Local treatment:
- physiotherapy
- Sympathectomy: medical or surgical
* Systemic Treatment: - Steroids
- Calcitonin: is the most widely used drug with many reports confirming its efficacy
Focal Osteoporosis
![Page 126: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/126.jpg)
AD
![Page 127: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/127.jpg)
AD
© Clinical Trial (Sawiki A. et al.1992) :
* Synthetic Salmon Calcitonin is not only potent inhibitor of the algodystroph
process but may also contribute in some was to the activation of the skeletal restoration normal bone density.
Clinical Rheumatology,1992
Algodystrophy
![Page 128: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/128.jpg)
AD
![Page 129: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/129.jpg)
AD
© Clinical Trial (Sawiki A. et al.1992) (Cont.):
* * A marked clinical improvement
occurred; pain diminished, motion range increased oedema, redness and hypothermia substantially decreased.
Clinical Rheumatology,1992
Algodystrophy
![Page 130: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/130.jpg)
ADFocal Osteoporosis
![Page 131: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/131.jpg)
AD
![Page 132: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/132.jpg)
AD
© Algodystrophy: * Clinical syndrome characterized by:
- Pain- Tenderness- Dystrophic skin changes- Swelling - Stiffness - Vascular instability
Focal Osteoporosis
![Page 133: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/133.jpg)
AD
© Algodystrophy: * Radiological changes include:
- Loss of bone density
- Patchy radio translucencies
- Subchondral radiio-translucencies
- Loss of trabecular definition
Focal Osteoporosis
![Page 134: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/134.jpg)
AD
Transient Osteoporosis
of the Hip in Pregnancy
Focal Osteoporosis
![Page 135: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/135.jpg)
AD
© Transient Osteoporosis of the Hip : * Occurs in women during third trimester.
* Clinical manifestations include hip pain and limitation of movements.
* ESR may be raised.
* X-ray shows osteoporsis particularly the femoral head.
Focal Osteoporosis
![Page 136: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/136.jpg)
ADFocal Osteoporosis
![Page 137: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/137.jpg)
AD
Calcitonin New interesting Publication
Calcitonin New interesting Publication
![Page 138: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/138.jpg)
AD
![Page 139: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/139.jpg)
AD
![Page 140: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/140.jpg)
AD
![Page 141: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/141.jpg)
AD
![Page 142: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/142.jpg)
Algodystrophy
Reflex sympathetic dystrophy PROF. HAZEM ABDEL-AZEEM
PROF. OF ORTH, SURGERY
CAIRO UNIVERSITY
![Page 143: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/143.jpg)
AD
Definition "Algodyitrophy is a clinical syndrome characterized by prominent locoregional pain, vasomotor and trophic changes and delayed recovery, occurring after even minor trauma or surgery
![Page 144: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/144.jpg)
Nomenclature of Algodystrophy
* Out of > 45 names the commonest are :- Algodystrophy
- Complex regional pain syndrome type 1 (CRPS1- port trauma or surgery)
- Complex regional pain syndrome type 2 (CRPS2- alter nerve Injury)
- Reflex sympathetic dystrophy
- Sudeks atrophy
![Page 145: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/145.jpg)
Nomenclature of Algodystrophy* In retrospective studies the incidence
was:- 1-2% after various fractures and- 2-5% alter peripheral nerve Injury.
* In prospective studies, the incidence was much higher:- 7-3SV. of Colles' fracture ,- 27% after stroke with shoulder trauma and- 8%after stroke when shoulder trauma was avoided.
![Page 146: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/146.jpg)
Associated events related to
Algodystrophy* Trauma:- without fracture
» minor trauma » major trauma
- withfracture» limbs » vertebra
* Neurological lesions* Spontaneous
* Other precipitating/ associated factors eg : - Surgery- Stroke - Coronary artery disease.
![Page 147: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/147.jpg)
AD
Incidence of Algodystrophy Event No. Pts Follow-
up S&S Prev. %
Stroke 136 24 W.
Shoulder- hand Sy 27%
Colles 100 12 W.
TendernessVasomotor Sy.StiffnessSwelling
24 %
Colles 60 9W.
Tenderness Vasomotor Sy.Stiffness
38%40 %40 %
Colles 274 52 W.
TendernessVasomotor Sy.StiffnessSwelling
36 %44 %37 %45 %
![Page 148: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/148.jpg)
ADIncidence after Colle´s fracture
![Page 149: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/149.jpg)
ADIncidence after Colle´s fracture
![Page 150: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/150.jpg)
ADPathophysiology The clinical signs suggest the involvement of
the neurological system, and
The scintigraphic and radiological changes
indicate increased vascularity and accelerated
bone loss.
Which of the changes is cause or secondary
remains, however, to be proven.
![Page 151: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/151.jpg)
ADPathophysiology The hypothesis of an abnormal sympathetic
nervous reflex Is, challenged by: The variable effect of local blockade of the sympathetic system
or of gympathectomy.
Furthermore, In a large group of patients with algodystrophy,
early symptoms of an exaggerated regional Inflammatory
response were found In most patients, but clinical symptoms of
a disturbance of the sympathetic nervous system, such as
hyperhydrosts, were only rarely present.
The lower level of noradrenallne In the affected site does not
support Increased sympathetic overactlvlty.
![Page 152: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/152.jpg)
ADPathophysiology Tissue injury in the inciting event, and biochemical processes have
been involved.
Recently α-adrenerglc receptors have been emphasized, in controlling
thermoregulatory modulation.
Psychological symptomps were found in up to 50% of the patients,
BUT many of them were described in patients with severe illness as
well.
The changes in bone density on X-ray, with patchy osteoporosis, are
considered to be secondary to an inflammation-like component of the
syndrome and to disuse.
![Page 153: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/153.jpg)
ADDIAGNOSIS No gold standard for diagnosis.
Diagnosis is based on the combination of clinical signs and in some,
cased by X-ray and radionuclide scintigraphic pictures.
In clinical research setting additional methods have been applied such as;
Thermography,
Volume measurement of the affected limb.
measurement of resting sweat.
Quantitative pseudomotor axon reflex tests.
Asymmetry, ultrasound, Doppler and bone densitometry.
![Page 154: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/154.jpg)
RISK FACTORS FOR DEVELOPING ALGODYSTROPHY
Some studies, (thawed that Collet' fracture as evaluated by severity (usingthe Frytanan's dassHlcatton) will associated with the severity of algodystrophy.
Risk factor* alter itroke Included subluxation and paresis of the shoulder
girdle, moderate •pasticlty and vliual disturbances.
Transient osteoporosls of the hip Is a typical presentation hi pregnancy or
early postpartum.
The hypothesis of a special personality structure for developingaigodystrophy has not been found in a large overview of the literature.
Patients with severe complications were younger,
Females, had more often lower limb Involvement or multiple localizations and had Initially a 'cold* presentation on clinical examination.
![Page 155: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/155.jpg)
Modified clinical diagnostic criteria Disproportionate pain to inciting event with:
- At least one symptom In each of the following categories:
• Sensory; hyperesthesla
• vasomotor : Temp. Asymmetry and /or skin colour changes and /or skin color asymm.
• Sweating /Oedema : Oedema and /or sweating changes and/or sweating asymm.
• Motor/ Trophic: Dei ease range of motion and /or motor dysfunction (weaqkness, tremor, dystonla) and / or trophic changes (hair ,nall, skin) B - Plus at least one sign In 2 or more of the same categories
![Page 156: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/156.jpg)
Radionuclide scintigraphy Typically, the scintigraphic analysis includes a
radionuclide angiogram, a blood pool or tissue phase image and a delayed image.Three stages have been described
increased perfusion with increased and delayed activity of bone images, followed by.
Normal perfusion with persistent changes in bone images and lastly,
Normal or decreased vascularity with normalization of the bone images.
Typical positive image can be supportive but it’s the absence does not rule out typical clinical presentation.
![Page 157: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/157.jpg)
Radionuclide changes Patchy or diffuse osteopenia are found in 50%
of cases.
The radiographic appearance is however non-specific.
Osteopenia may be seen 2 to 3 weeks after the onset of symptoms.
In a later stage: Affected bones may have a ground glass appearance.
cortical crosions around the joints andIncreased joint effusion.
![Page 158: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/158.jpg)
Radionuclide changes (Cont.)
Localized osteoprosis :
After 7 weeks, bone loss was significantly highrt in
patients with alogodystrophy at cortical (14% versus-6%, P<
0.05) and trabecular sites ( -23% versus- 10% p< 0.001) in
the forearm compared to patients without algodystrophy.
in patient without algodystrophy, bone loss recovered
after 19-32 weeks, in patients with algodystrophy, bone loss
persisted after 6 to 12 months.
![Page 159: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/159.jpg)
Clinical presentation
Algodystrophy
Swelling Pain
Tendernes
Vasomotor
disurbance
Frozen shoulder syndrome
Stiffness
AD
![Page 160: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/160.jpg)
SPECTRUM OF CLINICAL SIGNS AND
SYMPTOMS Algodystrophy typical occurs in an extermity after a sometimes trivial event, such as trauma or surgry:
The clinical picture includes the combinations of
o intense pain that is disropportionate to the incting event.
o Vasomotor changes with oedema and changes in skin colour and
temperature.
o Delayed functional recovery, and
o Various associated tropic changes
The key feature is disroprotionate pain, and this may be the initial
manifestation of algodystrophy.
![Page 161: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/161.jpg)
SPECTRUM OF CLINICAL SIGNS AND SYMPTOMS - The clinical picture of Algodystrophy is
different in children as compared to adults. It is
mostly characterised by hypothermia, and mild
and incomplete forms have been described
![Page 162: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/162.jpg)
SPECTRUM OF CLINICAL SIGNS AND SYMPTOMS Stages of Algodystrophy :
Stage I (weeks to months):
o Non-focal pain of often progressively increasing intensity that is
disproprtionate to the incliting evevt, associated with joint stiffness,
decreased rang of motion, increased skin temperature and dyshydrosis.
Stage II (several months):
o Persisting pain with tendency to decrease in most but not all cases, oedema
with thicking of the skin and fascia, and muscular atrophy. Development of
localized patchy osteoporosis.
Stage III :
o Persisting, atrophy of skin and muscles, stiffness of the joint, cooling of the
involved extermity.
![Page 163: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/163.jpg)
Long-term consequences
persists for > 1 year & may nead to loss of function
Bone loss Malunio Pain & stiffness
Deformity. Shortening of the radius.Radio-ulnar joint dislocation.
> 10% loss in cortical bone. > 25% loss in trabecular bone.
AD
![Page 164: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/164.jpg)
The patient need
inhibition of the algodystrophic process.
Relief of symptoms.
Restoration of normal density
![Page 165: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/165.jpg)
MANAGEMENT • Management of algodystrophy has been complicated by all the
above mentioned uncertainties
• Furthermore, management of chronic evolution can become
complicated by associated psychosodal problems of the
patient
• Physical therapy Is suggested as the mainstay of therapy, but
no controlled trial Is available,
• Caldtonln Induced a rapid decline In pain In 64% of patients
compared to 23% on placebo after 2 weeks (P < 0,001),
• Intranasal calcltonln was superior to placebo In ameliorating
pain and mobility, and resulted In Increased work ability after
60 days,
![Page 166: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/166.jpg)
Role of Miacalcic
Miacalcic
Relieves oedema
Inhibits the Alogodystrophy
process Relives pain
Increases the rang of
movement Helps in restoration
of normal bone density
Reduces redness
& hypothemia
AD
![Page 167: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/167.jpg)
Miacalcic in Algodystrophy• Clinical Trial (Sawiki A. et al.1992):
* Synthetic Salmon Calcitonin is not only a po inhibitor
of the algodystrophic process but may also contribute
in some way to the activation of the skeletal
restoration of normal bone density.
* A marked clinical improvement occurred; pain
diminished, motion range increased oedema, redness
and hypothermia substantially decreased.
![Page 168: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/168.jpg)
Miacalcic Relives pain and improves
the rang of movement in
algodystrophy.
![Page 169: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/169.jpg)
AD
“ Calcitonin has proved to be the most effective agent in the treatment of Sudeck's disease. It proves microcirculatory disturbances.
• Reduces bone pain.
•Inhibits the pathologically increased bone resorption"
Miacalcic Relives pain and improves
the rang of movement in
algodystrophy.
![Page 170: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/170.jpg)
Thank You
![Page 171: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/171.jpg)
AD
![Page 172: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/172.jpg)
AD
![Page 173: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/173.jpg)
AD
![Page 174: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/174.jpg)
AD
![Page 175: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/175.jpg)
AD
![Page 176: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/176.jpg)
AD
![Page 177: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/177.jpg)
AD
![Page 178: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/178.jpg)
AD
![Page 179: 1-17 Algodystrophy---](https://reader033.vdocuments.mx/reader033/viewer/2022061119/546a58b5b4af9f3b388b4710/html5/thumbnails/179.jpg)
AD